New Zealand Health Terminology Service (NZHTS) Implementation Guide
0.1.0 - ci-build
New Zealand Health Terminology Service (NZHTS) Implementation Guide
0.1.0 - ci-build
New Zealand Health Terminology Service (NZHTS) Implementation Guide, published by Health New Zealand | Te Whatu Ora. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/daniel-thomson/nzhts/ and changes regularly. See the Directory of published versions
| Active as of 2024-11-11 |
<CodeSystem xmlns="http://hl7.org/fhir">
<id value="canshare-unpublished-concepts"/>
<meta>
<versionId value="1"/>
<lastUpdated value="2024-11-05T17:14:43.036+13:00"/>
</meta>
<url value="http://canshare.co.nz/fhir/CodeSystem/snomed-unpublished"/>
<identifier>
<system value="http://canshare.co.nz/fhir/NamingSystem/codesystems"/>
<value value="canshare-unpublished-concepts"/>
</identifier>
<version value="0.1.0"/>
<name value="Canshare_unpublished_concepts"/>
<title value="Concepts that are not yet formally published"/>
<status value="active"/>
<date value="2024-11-11T02:01:44+00:00"/>
<publisher value="Health New Zealand | Te Whatu Ora"/>
<contact>
<name value="Health New Zealand | Te Whatu Ora"/>
<telecom>
<system value="url"/>
<value value="https://www.tewhatuora.govt.nz/"/>
</telecom>
</contact>
<caseSensitive value="true"/>
<content value="complete"/>
<concept>
<code value="392611000210105"/>
<display value="BR Metastatic - cARBOplatin [2 AUC] and gemcitabine"/>
</concept>
<concept>
<code value="392601000210108"/>
<display value="BR Metastatic - ribociclib"/>
</concept>
<concept>
<code value="392591000210103"/>
<display value="LEU - GMALL T-LBL 1/2004 HDMTX/ASP [55 years and under]"/>
</concept>
<concept>
<code value="392581000210100"/>
<display
value="LEU - GMALL T-LBL 1/2004 Consolidation [55 years and under]"/>
</concept>
<concept>
<code value="392571000210102"/>
<display
value="LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [55 years and under]"/>
</concept>
<concept>
<code value="392561000210108"/>
<display
value="LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under]"/>
</concept>
<concept>
<code value="392551000210105"/>
<display value="LEU - GMALL T-LBL 1/2004 triple prophylaxis"/>
</concept>
<concept>
<code value="392541000210107"/>
<display value="LEU - GMALL T-LBL 1/2004 CYCLO/ARAC"/>
</concept>
<concept>
<code value="392531000210104"/>
<display value="LEU - GMALL T-LBL 1/2004 VM26/ARAC"/>
</concept>
<concept>
<code value="392521000210101"/>
<display value="LEU - GMALL T-LBL 1/2004 Reinduction"/>
</concept>
<concept>
<code value="392511000210106"/>
<display value="LEU - GMALL T-LBL 1/2004 HDMTX/ASP [over 55 years]"/>
</concept>
<concept>
<code value="392501000210109"/>
<display
value="LEU - GMALL T-LBL 1/2004 Consolidation I [over 55 years]"/>
</concept>
<concept>
<code value="392491000210104"/>
<display
value="LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [over 55 years]"/>
</concept>
<concept>
<code value="392481000210101"/>
<display
value="LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years]"/>
</concept>
<concept>
<code value="392471000210103"/>
<display
value="LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392461000210109"/>
<display
value="LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="392451000210106"/>
<display
value="LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392441000210108"/>
<display
value="LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="392431000210100"/>
<display
value="LEU ALL - HyperCVAD with pegaspargase Part A and B followed by POMP Maintenance [under 40 years]"/>
</concept>
<concept>
<code value="392421000210102"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="392411000210107"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="392401000210105"/>
<display
value="LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [not for transplant]"/>
</concept>
<concept>
<code value="392391000210107"/>
<display
value="LEU - UKALL14 with RITUximab [not for transplant] Maintenance"/>
</concept>
<concept>
<code value="392381000210105"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="392371000210108"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="392361000210102"/>
<display
value="LEU - UKALL14 with RITUximab [not for transplant] Phase 2 Induction"/>
</concept>
<concept>
<code value="392351000210100"/>
<display
value="LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [not for transplant]"/>
</concept>
<concept>
<code value="392341000210103"/>
<display
value="LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392331000210106"/>
<display
value="LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="392321000210109"/>
<display
value="LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392311000210104"/>
<display
value="LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="392301000210101"/>
<display
value="LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [60 years and under]"/>
</concept>
<concept>
<code value="392291000210100"/>
<display
value="LEU - HyperCVAD with RITUximab [over 60 years] Part B with Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="392281000210102"/>
<display
value="LEU - HyperCVAD Part B with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="391941000210106"/>
<display
value="LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="391931000210103"/>
<display
value="LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="391921000210100"/>
<display
value="LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [over 60 years]"/>
</concept>
<concept>
<code value="391911000210105"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="391901000210108"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] Consolidation [Cycle 1 and 2]"/>
</concept>
<concept>
<code value="391891000210107"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="391881000210105"/>
<display
value="LEU - UKALL14 with RITUximab [40 years and under] Phase 1 Induction"/>
</concept>
<concept>
<code value="391871000210108"/>
<display
value="LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [for transplant]"/>
</concept>
<concept>
<code value="391861000210102"/>
<display
value="LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [40 years and under]"/>
</concept>
<concept>
<code value="391851000210100"/>
<display
value="LEU - UKALL14 Consolidation [Cycle 1] [40 years and under]"/>
</concept>
<concept>
<code value="391841000210103"/>
<display
value="LEU - UKALL14 Intensification/CNS prophylaxis [40 years and under]"/>
</concept>
<concept>
<code value="391831000210106"/>
<display value="LEU - UKALL14 Phase 1 Induction [40 years and under]"/>
</concept>
<concept>
<code value="391821000210109"/>
<display value="LEU ALL - UKALL14 [40 years and under]"/>
</concept>
<concept>
<code value="391811000210104"/>
<display value="LEU - UKALL14 with RITUximab Consolidation [Cycle 4]"/>
</concept>
<concept>
<code value="391801000210101"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="391791000210100"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] Consolidation [Cycle 1 and 2]"/>
</concept>
<concept>
<code value="391781000210102"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="391771000210104"/>
<display
value="LEU - UKALL14 with RITUximab [for transplant] Phase 2 Induction"/>
</concept>
<concept>
<code value="391761000210105"/>
<display
value="LEU - UKALL14 with RITUximab [over 40 years] Phase 1 Induction"/>
</concept>
<concept>
<code value="391751000210107"/>
<display
value="LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant]"/>
</concept>
<concept>
<code value="391741000210109"/>
<display value="LEU - AIDA consolidation 3 [over 70 years]"/>
</concept>
<concept>
<code value="391731000210101"/>
<display value="LEU - AIDA consolidation 2 [over 70 years]"/>
</concept>
<concept>
<code value="391721000210103"/>
<display value="LEU - AIDA consolidation 1 [over 70 years]"/>
</concept>
<concept>
<code value="391711000210108"/>
<display value="LEU - AIDA induction [over 70 years]"/>
</concept>
<concept>
<code value="391701000210106"/>
<display
value="LEU APL - AIDA induction and consolidations 1, 2 and 3 [over 70 years]"/>
</concept>
<concept>
<code value="391691000210106"/>
<display
value="LEU AML - DA+GO-1 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]"/>
</concept>
<concept>
<code value="391681000210109"/>
<display
value="LEU - Pethema LPA2005 maintenance [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391671000210107"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391661000210101"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391621000210108"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391601000210100"/>
<display
value="LEU - Pethema LPA2005 induction [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391591000210105"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [low risk]"/>
</concept>
<concept>
<code value="391581000210108"/>
<display
value="LEU - Pethema LPA2005 maintenance [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391571000210106"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391561000210100"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391551000210103"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391541000210101"/>
<display
value="LEU - Pethema LPA2005 induction [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391531000210109"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [low risk]"/>
</concept>
<concept>
<code value="391521000210107"/>
<display
value="LEU - Pethema LPA2005 maintenance [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391511000210102"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391501000210104"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391491000210109"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391481000210107"/>
<display
value="LEU - Pethema LPA2005 induction [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391471000210105"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk]"/>
</concept>
<concept>
<code value="391461000210104"/>
<display value="GU GCT Seminoma Adjuvant - cARBOplatin [7 AUC]"/>
</concept>
<concept>
<code value="391451000210102"/>
<display value="GU URO Advanced - cISplatin and gemcitabine"/>
</concept>
<concept>
<code value="391441000210100"/>
<display
value="GU URO Advanced - cISplatin [split dose] and gemcitabine"/>
</concept>
<concept>
<code value="391431000210108"/>
<display
value="GU Upper Tract Urothelial Adjuvant - cISplatin [split dose] and gemcitabine"/>
</concept>
<concept>
<code value="391421000210106"/>
<display
value="GU GCT Metastatic - TIP [PACLItaxel, IFOSFamide and cISplatin]"/>
</concept>
<concept>
<code value="391411000210101"/>
<display
value="LEU - Pethema LPA2005 maintenance [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312741000210103"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312731000210106"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312721000210109"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312711000210104"/>
<display
value="LEU - Pethema LPA2005 induction [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312701000210101"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [intermediate risk]"/>
</concept>
<concept>
<code value="312691000210101"/>
<display
value="LEU - Pethema LPA2005 maintenance [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312681000210103"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312671000210100"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312661000210106"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312651000210108"/>
<display
value="LEU - Pethema LPA2005 induction [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312631000210102"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [under 60 years] [high risk]"/>
</concept>
<concept>
<code value="312621000210104"/>
<display
value="LEU - Pethema LPA2005 maintenance [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312611000210109"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312601000210107"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312591000210102"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312581000210104"/>
<display
value="LEU - Pethema LPA2005 induction [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312571000210101"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [60 to 70 years] [high risk]"/>
</concept>
<concept>
<code value="312561000210107"/>
<display value="LEU - UKALL14 Maintenance"/>
</concept>
<concept>
<code value="312551000210109"/>
<display value="LEU - UKALL14 Consolidation [Cycle 4]"/>
</concept>
<concept>
<code value="312541000210106"/>
<display
value="LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [over 40 years]"/>
</concept>
<concept>
<code value="312531000210103"/>
<display value="LEU - UKALL14 Consolidation [Cycle 2]"/>
</concept>
<concept>
<code value="312521000210100"/>
<display value="LEU - UKALL14 Consolidation [Cycle 1] [over 40 years]"/>
</concept>
<concept>
<code value="312511000210105"/>
<display
value="LEU - UKALL14 Intensification/CNS prophylaxis [over 40 years]"/>
</concept>
<concept>
<code value="312501000210108"/>
<display value="LEU - UKALL14 - Phase 2 Induction"/>
</concept>
<concept>
<code value="312491000210103"/>
<display value="LEU - UKALL14 [over 40 years] - Phase 1 Induction"/>
</concept>
<concept>
<code value="312481000210100"/>
<display value="LEU ALL - UKALL14 [over 40 years]"/>
</concept>
<concept>
<code value="312471000210102"/>
<display
value="LYM NHL B-cell - O-CHOP21 [oBINUTUZumab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="312461000210108"/>
<display value="LYM - DA-R-EPOCH LEVEL 6"/>
</concept>
<concept>
<code value="312451000210105"/>
<display value="LYM - DA-R-EPOCH LEVEL 5"/>
</concept>
<concept>
<code value="312441000210107"/>
<display value="LYM - DA-R-EPOCH LEVEL 4"/>
</concept>
<concept>
<code value="312431000210104"/>
<display value="LYM - DA-R-EPOCH LEVEL 3"/>
</concept>
<concept>
<code value="312421000210101"/>
<display value="LYM - DA-R-EPOCH LEVEL 2"/>
</concept>
<concept>
<code value="312411000210106"/>
<display value="LYM - DA-R-EPOCH LEVEL minus 3"/>
</concept>
<concept>
<code value="312401000210109"/>
<display value="LYM - DA-R-EPOCH LEVEL minus 2"/>
</concept>
<concept>
<code value="312391000210106"/>
<display value="LYM - DA-R-EPOCH LEVEL minus 1"/>
</concept>
<concept>
<code value="312381000210109"/>
<display value="LYM - DA-R-EPOCH LEVEL 1"/>
</concept>
<concept>
<code value="312371000210107"/>
<display
value="LYM NHL B-cell - DA-R-EPOCH [Dose-adjusted RITUximab, etoposide, prEDNIsone, vinCRISTine, CYCLOPHOSPHamide and DOXOrubicin] [9 levels]"/>
</concept>
<concept>
<code value="312361000210101"/>
<display
value="LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="312351000210104"/>
<display
value="LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="312341000210102"/>
<display
value="LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="312331000210105"/>
<display
value="LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="312321000210108"/>
<display
value="LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [60 years and under]"/>
</concept>
<concept>
<code value="312311000210103"/>
<display value="LEU - HyperCVAD POMP Maintenance"/>
</concept>
<concept>
<code value="312301000210100"/>
<display
value="LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="312291000210104"/>
<display
value="LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="312281000210101"/>
<display
value="LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis High Risk"/>
</concept>
<concept>
<code value="312271000210103"/>
<display
value="LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]"/>
</concept>
<concept>
<code value="312261000210109"/>
<display
value="LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [over 60 years]"/>
</concept>
<concept>
<code value="312251000210106"/>
<display
value="SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q2W]"/>
</concept>
<concept>
<code value="312241000210108"/>
<display value="SAR Ewing sarcoma - VAC, VC and IE [Q2W]"/>
</concept>
<concept>
<code value="312231000210100"/>
<display
value="SAR - VAC + VV [vinCRISTine day 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312221000210102"/>
<display
value="SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312211000210107"/>
<display
value="SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q3W] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312201000210105"/>
<display
value="SAR - IE [IFOSFamide and etoposide] [Q3W] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312191000210108"/>
<display
value="SAR - IE [IFOSFamide and etoposide] [Q2W] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312181000210106"/>
<display
value="SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q2W] ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312171000210109"/>
<display
value="SAR - vinCRISTine days 1 and 8 and irinotecan ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312161000210103"/>
<display
value="SAR - vinCRISTine days 1, 8 and 15 and irinotecan ARST0431 [high risk]"/>
</concept>
<concept>
<code value="312151000210101"/>
<display
value="SAR Rhabdomyosarcoma - vinCRISTine, irinotecan, IFOSFamide, etoposide, DOXOrubicin, CYCLOPHOSPHamide and daCTINomycin [ARST0431] [high risk]"/>
</concept>
<concept>
<code value="312141000210104"/>
<display
value="SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q3W]"/>
</concept>
<concept>
<code value="312131000210107"/>
<display value="SAR Ewing sarcoma - VAC, VC and IE [Q3W]"/>
</concept>
<concept>
<code value="312121000210105"/>
<display value="SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q3W]"/>
</concept>
<concept>
<code value="312111000210100"/>
<display value="SAR - IE [IFOSfamide and etoposide][Q3W]"/>
</concept>
<concept>
<code value="312101000210102"/>
<display
value="SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] [Q3W]"/>
</concept>
<concept>
<code value="312091000210109"/>
<display value="SAR Ewing sarcoma - VDC, VC and IE [Q3W]"/>
</concept>
<concept>
<code value="312081000210107"/>
<display value="SAR - MA [metHOTREXATe and DOXOrubicin]"/>
</concept>
<concept>
<code value="312071000210105"/>
<display value="SAR - MAP [metHOTREXATe, DOXOrubicin and cISplatin]"/>
</concept>
<concept>
<code value="312061000210104"/>
<display
value="SAR Osteosarcoma - MAP [metHOTREXATe, DOXOrubicin and cISplatin]"/>
</concept>
<concept>
<code value="312051000210102"/>
<display value="PCN MM - pamidronate 90mg Q4W"/>
</concept>
<concept>
<code value="312041000210100"/>
<display value="LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2]"/>
</concept>
<concept>
<code value="312031000210108"/>
<display value="LEU ALL precursor B-cell - blinatumomab [CNS3]"/>
</concept>
<concept>
<code value="312021000210106"/>
<display value="CRC REC Locally advanced - dostarlimab"/>
</concept>
<concept>
<code value="312011000210101"/>
<display value="CRC - mFOLFOX6 [low dose foliNIc acid] 9 cycles"/>
</concept>
<concept>
<code value="312001000210103"/>
<display value="CRC - mFOLFOX6 [high dose foliNIc acid] 9 cycles"/>
</concept>
<concept>
<code value="311991000210101"/>
<display value="CRC - CAPOX 6 cycles"/>
</concept>
<concept>
<code value="311981000210103"/>
<display value="CRC REC Neoadjuvant - RAPIDO Total Neoadjuvant Therapy"/>
</concept>
<concept>
<code value="311971000210100"/>
<display value="CRC Metastatic - irinotecan [Q3W] dose reduced"/>
</concept>
<concept>
<code value="311961000210106"/>
<display value="CRC Metastatic - CETUximab Q2W"/>
</concept>
<concept>
<code value="311951000210108"/>
<display value="CRC Metastatic - trifluridine/tipiracil and beVACizumab"/>
</concept>
<concept>
<code value="311941000210105"/>
<display value="CRC Metastatic - trifluridine/tipiracil"/>
</concept>
<concept>
<code value="311931000210102"/>
<display value="CRC Metastatic - pembrolizumab Q6W [flat dosing]"/>
</concept>
<concept>
<code value="311921000210104"/>
<display value="CRC Locally advanced - ipilimumab and nivolumab"/>
</concept>
<concept>
<code value="311911000210109"/>
<display value="CRC Metastatic - pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="311901000210107"/>
<display value="CRC Metastatic - CETUximab [Q2W] and encorafenib"/>
</concept>
<concept>
<code value="311891000210106"/>
<display value="CRC Metastatic - CETUximab [Q2W] and daBRAFEnib"/>
</concept>
<concept>
<code value="311881000210109"/>
<display value="LEU - AIDA consolidation 3 [70 years and under]"/>
</concept>
<concept>
<code value="311871000210107"/>
<display value="LEU - AIDA consolidation 2 [70 years and under]"/>
</concept>
<concept>
<code value="311861000210101"/>
<display value="LEU - AIDA consolidation 1 [70 years and under]"/>
</concept>
<concept>
<code value="311851000210104"/>
<display value="LEU - AIDA induction [70 years and under]"/>
</concept>
<concept>
<code value="311841000210102"/>
<display
value="LEU APL - AIDA induction and consolidations 1, 2 and 3 [70 years and under]"/>
</concept>
<concept>
<code value="311831000210105"/>
<display
value="LEU - arsenic trioxide and tretinoin consolidation [AML17]"/>
</concept>
<concept>
<code value="311821000210108"/>
<display value="LEU - arsenic trioxide and tretinoin induction [AML17]"/>
</concept>
<concept>
<code value="311811000210103"/>
<display
value="LEU APL - arsenic trioxide and tretinoin induction followed by consolidation [AML17]"/>
</concept>
<concept>
<code value="311801000210100"/>
<display value="LEU - APML4 maintenance [61 to 70 years]"/>
</concept>
<concept>
<code value="311791000210104"/>
<display value="LEU - APML4 consolidation 2 [61 to 70 years]"/>
</concept>
<concept>
<code value="311781000210101"/>
<display value="LEU - APML4 consolidation 1 [61 to 70 years]"/>
</concept>
<concept>
<code value="311771000210103"/>
<display value="LEU - APML4 induction [61 to 70 years]"/>
</concept>
<concept>
<code value="311761000210109"/>
<display
value="LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [61 to 70 years]"/>
</concept>
<concept>
<code value="311751000210106"/>
<display value="LEU - APML4 maintenance [over 70 years]"/>
</concept>
<concept>
<code value="311741000210108"/>
<display value="LEU - APML4 consolidation 2 [over 70 years]"/>
</concept>
<concept>
<code value="311721000210102"/>
<display value="LEU - APML4 consolidation 1 [over 70 years]"/>
</concept>
<concept>
<code value="311711000210107"/>
<display value="LEU - APML4 induction [over 70 years]"/>
</concept>
<concept>
<code value="311701000210105"/>
<display
value="LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [over 70 years]"/>
</concept>
<concept>
<code value="311691000210105"/>
<display
value="LEU - Pethema LPA2005 maintenance [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311681000210108"/>
<display
value="LEU - Pethema LPA2005 consolidation 3 [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311671000210106"/>
<display
value="LEU - Pethema LPA2005 consolidation 2 [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311661000210100"/>
<display
value="LEU - Pethema LPA2005 consolidation 1 [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311651000210103"/>
<display
value="LEU - Pethema LPA2005 induction [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311641000210101"/>
<display
value="LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [intermediate risk]"/>
</concept>
<concept>
<code value="311631000210109"/>
<display value="LEU HCL - cladribine and RITUximab"/>
</concept>
<concept>
<code value="311621000210107"/>
<display
value="LEU - arsenic trioxide and tretinoin consolidation [standard risk]"/>
</concept>
<concept>
<code value="311611000210102"/>
<display
value="LEU - arsenic trioxide, tretinoin and prEDNISone induction [standard risk]"/>
</concept>
<concept>
<code value="311601000210104"/>
<display
value="LEU APL - arsenic trioxide, tretinoin and prEDNISone induction followed by consolidation [standard risk]"/>
</concept>
<concept>
<code value="311591000210109"/>
<display value="LEU - APML4 maintenance [60 years and under]"/>
</concept>
<concept>
<code value="311581000210107"/>
<display value="LEU - APML4 consolidation 2 [60 years and under]"/>
</concept>
<concept>
<code value="311571000210105"/>
<display value="LEU - APML4 consolidation 1 [60 years and under]"/>
</concept>
<concept>
<code value="311561000210104"/>
<display value="LEU - APML4 induction [60 years and under]"/>
</concept>
<concept>
<code value="311551000210102"/>
<display
value="LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [60 years and under]"/>
</concept>
<concept>
<code value="311541000210100"/>
<display value="LEU - UKALL14 with daSATinib Maintenance"/>
</concept>
<concept>
<code value="311531000210108"/>
<display value="LEU - UKALL14 with daSATinib Consolidation [Cycle 4]"/>
</concept>
<concept>
<code value="311521000210106"/>
<display
value="LEU - UKALL14 with daSATinib consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="311511000210101"/>
<display
value="LEU - UKALL14 with daSATinib Consolidation [Cycle 1 and 2]"/>
</concept>
<concept>
<code value="311501000210103"/>
<display
value="LEU - UKALL14 with daSATinib Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="311491000210108"/>
<display value="LEU - UKALL14 with daSATinib Phase 2 Induction"/>
</concept>
<concept>
<code value="311481000210106"/>
<display value="LEU - UKALL14 with daSATinib Phase 1 Induction"/>
</concept>
<concept>
<code value="311471000210109"/>
<display
value="LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with daSATinib"/>
</concept>
<concept>
<code value="311461000210103"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Maintenance"/>
</concept>
<concept>
<code value="311451000210101"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Consolidation/delayed intensification [Cycle 3]"/>
</concept>
<concept>
<code value="311441000210104"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="311431000210107"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Phase 2 Induction"/>
</concept>
<concept>
<code value="311421000210105"/>
<display
value="LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [not for transplant]"/>
</concept>
<concept>
<code value="311411000210100"/>
<display
value="LYM - High dose cytarabine [2000mg/m2 TWICE daily days 1 and 2] Consolidation"/>
</concept>
<concept>
<code value="311401000210102"/>
<display value="LYM - R-MPV alternating with R-MV"/>
</concept>
<concept>
<code value="311391000210100"/>
<display
value="LYM NHL B-cell PCNSL - R-MPV [RITUximab, metHOTREXATe, procarbazine and vinCRISTine] followed by high dose cytarabine"/>
</concept>
<concept>
<code value="311381000210102"/>
<display value="LYM - EA [etoposide and cytarabine]"/>
</concept>
<concept>
<code value="311371000210104"/>
<display value="LYM - MT-R"/>
</concept>
<concept>
<code value="311361000210105"/>
<display
value="LYM NHL B-cell PCNSL - MT-R [metHOTREXate, temozolomide and RITUximab] followed by EA [etoposide and cytarabine]"/>
</concept>
<concept>
<code value="311351000210107"/>
<display
value="LYM NHL B-cell Primary Testicular - high dose metHOTREXATe [CNS prophylaxis]"/>
</concept>
<concept>
<code value="311341000210109"/>
<display
value="LYM NHL B-cell PCNSL - MATRix [metHOTREXATe, cytarabine, thiotepa and RITUximab] Induction"/>
</concept>
<concept>
<code value="311331000210101"/>
<display value="LEU CLL Relapsed - aLEMTUzumab [subcut]"/>
</concept>
<concept>
<code value="311321000210103"/>
<display value="LEU CLL - venetoclax and oBINUTUZumab"/>
</concept>
<concept>
<code value="311311000210108"/>
<display value="LEU CLL - RITUximab and bendamustine"/>
</concept>
<concept>
<code value="311301000210106"/>
<display value="LEU CLL Relapsed - aLEMTUzumab [IV]"/>
</concept>
<concept>
<code value="311291000210107"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 4]"/>
</concept>
<concept>
<code value="311281000210105"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib consolidation/delayed intensification [Cycle 3] [for transplant]"/>
</concept>
<concept>
<code value="311271000210108"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 1 and 2]"/>
</concept>
<concept>
<code value="311261000210102"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib [for transplant] Intensification/CNS prophylaxis"/>
</concept>
<concept>
<code value="311251000210100"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib Phase 2 Induction [for transplant]"/>
</concept>
<concept>
<code value="311241000210103"/>
<display
value="LEU - UKALL14 with RITUximab and daSATinib Phase 1 Induction"/>
</concept>
<concept>
<code value="311231000210106"/>
<display value="LEU - dexamethasone 6 mg/m2 days 1 to 5"/>
</concept>
<concept>
<code value="311221000210109"/>
<display
value="LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [for transplant]"/>
</concept>
<concept>
<code value="311211000210104"/>
<display value="LYM - oBINUTUZumab maintenance"/>
</concept>
<concept>
<code value="311201000210101"/>
<display value="LYM - bendamustine and oBINUTUZumab"/>
</concept>
<concept>
<code value="311191000210103"/>
<display value="LYM NHL B-cell - bendamustine and oBINUTUZumab"/>
</concept>
<concept>
<code value="311181000210100"/>
<display
value="LYM NHL NK/T-cell Extra Nodal - DDGP [dexamethasone, cISplatin, gemcitabine and pegaspargase]"/>
</concept>
<concept>
<code value="311171000210102"/>
<display value="LEU CLL - venetoclax and RITUximab"/>
</concept>
<concept>
<code value="311161000210108"/>
<display value="LEU - imatinib 600"/>
</concept>
<concept>
<code value="311151000210105"/>
<display value="LEU - imatinib 400"/>
</concept>
<concept>
<code value="311141000210107"/>
<display value="LEU CML - imatinib"/>
</concept>
<concept>
<code value="311131000210104"/>
<display
value="LYM NHL B-cell - Flyer R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] followed by RITUximab"/>
</concept>
<concept>
<code value="311121000210101"/>
<display value="LEU - UKALL60+ Maintenance"/>
</concept>
<concept>
<code value="311111000210106"/>
<display value="LEU - UKALL60+ Consolidation"/>
</concept>
<concept>
<code value="311101000210109"/>
<display value="LEU - UKALL60+ Phase 2 Induction"/>
</concept>
<concept>
<code value="311091000210102"/>
<display value="LEU - UKALL60+ Phase 1 Induction"/>
</concept>
<concept>
<code value="311081000210104"/>
<display value="LEU ALL - UKALL60+ [non-intensive]"/>
</concept>
<concept>
<code value="311071000210101"/>
<display value="LEU - UKALL60+ with daSATinib Maintenance"/>
</concept>
<concept>
<code value="311061000210107"/>
<display value="LEU - UKALL60+ with daSATinib Consolidation"/>
</concept>
<concept>
<code value="311051000210109"/>
<display value="LEU - UKALL60+ with daSATinib Phase 2 Induction"/>
</concept>
<concept>
<code value="311041000210106"/>
<display value="LEU - UKALL60+ with daSATinib Phase 1 Induction"/>
</concept>
<concept>
<code value="311031000210103"/>
<display value="LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib"/>
</concept>
<concept>
<code value="311021000210100"/>
<display value="LEU - UKALL60+ with imatinib Maintenance"/>
</concept>
<concept>
<code value="311011000210105"/>
<display value="LEU - UKALL60+ with imatinib Consolidation"/>
</concept>
<concept>
<code value="311001000210108"/>
<display value="LEU - UKALL60+ with imatinib Phase 2 Induction"/>
</concept>
<concept>
<code value="310991000210109"/>
<display value="LEU - UKALL60+ with imatinib Phase 1 Induction"/>
</concept>
<concept>
<code value="310981000210107"/>
<display value="LEU - dexamethasone 6 mg/m2 [max 10 mg] days 1 to 5"/>
</concept>
<concept>
<code value="310971000210105"/>
<display value="LEU ALL BCR-ABL1+ - UKALL60+ with imatinib"/>
</concept>
<concept>
<code value="310961000210104"/>
<display
value="LEU AML - DA+GO-2 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]"/>
</concept>
<concept>
<code value="310951000210102"/>
<display
value="LEU AML - 7 + 3 IDA [IDArubicin and cytarabine] induction"/>
</concept>
<concept>
<code value="310941000210100"/>
<display
value="LEU - High dose cytarabine [1000mg/m2 TWICE daily days 1 to 6] consolidation"/>
</concept>
<concept>
<code value="310931000210108"/>
<display
value="LEU - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction [over 60 years]"/>
</concept>
<concept>
<code value="303631000210108"/>
<display
value="LEU AML - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction followed by high dose cytarabine consolidation [over 60 years]"/>
</concept>
<concept>
<code value="303621000210106"/>
<display
value="LEU - High dose cytarabine and midostaurin consolidation [under 60 years]"/>
</concept>
<concept>
<code value="303611000210101"/>
<display
value="LEU - DAUNOrubicin, cytarabine and midostaurin induction [under 60 years]"/>
</concept>
<concept>
<code value="303601000210103"/>
<display
value="LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [under 60 years]"/>
</concept>
<concept>
<code value="303591000210108"/>
<display value="LEU - Midostaurin maintenance"/>
</concept>
<concept>
<code value="303581000210106"/>
<display
value="LEU - High dose cytarabine and midostaurin consolidation [60 years and over]"/>
</concept>
<concept>
<code value="303571000210109"/>
<display
value="LEU - DAUNOrubicin, cytarabine and midostaurin induction [60 years and over]"/>
</concept>
<concept>
<code value="303561000210103"/>
<display
value="LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [60 years and over]"/>
</concept>
<concept>
<code value="303551000210101"/>
<display
value="LEU - Manchester Protocol [mitoxantrone and cytarabine IV] consolidation"/>
</concept>
<concept>
<code value="303541000210104"/>
<display
value="LEU - Manchester Protocol [mitoxantrone and cytarabine IV] induction"/>
</concept>
<concept>
<code value="303531000210107"/>
<display
value="LEU AML - Manchester Protocol [mitoxantrone and cytarabine IV] induction followed by consolidation"/>
</concept>
<concept>
<code value="303521000210105"/>
<display
value="LYM NHL B-cell PCNSL Relapsed - R-IE [RITUximab, IFOSFamide and etoposide]"/>
</concept>
<concept>
<code value="303511000210100"/>
<display value="LYM - procarbazine [100 mg daily for 5 days]"/>
</concept>
<concept>
<code value="303501000210102"/>
<display
value="LYM - R-MP [RITUximab, metHOTREXATe, procarbazine] [65 years and over]"/>
</concept>
<concept>
<code value="303491000210107"/>
<display
value="LYM NHL B-cell PCNSL - R-MP [RITUximab, metHOTREXATe and procarbazine] followed by procarbazine maintenance [65 years and over]"/>
</concept>
<concept>
<code value="303481000210105"/>
<display value="LYM NHL B-cell - RITUximab and bendamustine"/>
</concept>
<concept>
<code value="303471000210108"/>
<display value="LYM NHL B-cell - RITUximab Maintenance Q8W"/>
</concept>
<concept>
<code value="303461000210102"/>
<display value="LYM NHL B-cell - RITUximab Q1W"/>
</concept>
<concept>
<code value="303451000210100"/>
<display
value="GYN CX Advanced - cISplatin, PACLItaxel, beVACizumab and pembrolizumab"/>
</concept>
<concept>
<code value="303441000210103"/>
<display
value="GYN CX Advanced - cISplatin, PACLItaxel and pembrolizumab"/>
</concept>
<concept>
<code value="265711000210103"/>
<display
value="Neuroendocrine carcinoma - cISplatin and etoposide 60/120 chemoradiation"/>
</concept>
<concept>
<code value="265701000210100"/>
<display
value="Neuroendocrine carcinoma - cISplatin and etoposide 80/100 chemoradiation"/>
</concept>
<concept>
<code value="265691000210100"/>
<display value="Desmoid fibromatosis - metHOTREXATe and vinBLASTine"/>
</concept>
<concept>
<code value="265681000210102"/>
<display value="SAR STS Metastatic - DOCEtaxel and gemcitabine 900"/>
</concept>
<concept>
<code value="265671000210104"/>
<display
value="SAR STS Metastatic - DOCEtaxel and gemcitabine 675 [GeDDis]"/>
</concept>
<concept>
<code value="265661000210105"/>
<display value="SAR STS Advanced - trabectedin"/>
</concept>
<concept>
<code value="265651000210107"/>
<display value="SAR STS Advanced - pAZOPanib"/>
</concept>
<concept>
<code value="265641000210109"/>
<display value="SAR STS Advanced - IFOSFamide [3-day]"/>
</concept>
<concept>
<code value="265631000210101"/>
<display value="SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q2W]"/>
</concept>
<concept>
<code value="265621000210103"/>
<display value="SAR - IE [IFOSfamide and etoposide][Q2W]"/>
</concept>
<concept>
<code value="265611000210108"/>
<display
value="SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] with dexrazoxane [Q2W]"/>
</concept>
<concept>
<code value="265601000210106"/>
<display
value="SAR Ewing sarcoma - VDC with dexrazoxane, VC and IE [Q2W]"/>
</concept>
<concept>
<code value="265591000210101"/>
<display value="SAR STS Advanced - DOXOrubicin and IFOSFamide 25/3000"/>
</concept>
<concept>
<code value="265581000210103"/>
<display value="SAR STS Advanced - DOXOrubicin and IFOSFamide 20/2000"/>
</concept>
<concept>
<code value="265571000210100"/>
<display
value="SAR Osteosarcoma Advanced - DOXOrubicin [1-day dosing] and cISplatin"/>
</concept>
<concept>
<code value="265561000210106"/>
<display
value="SAR Ewing sarcoma Relapsed - CYCLOPHOSPHamide and topotecan"/>
</concept>
<concept>
<code value="265551000210108"/>
<display
value="SAR Rhabdomyosarcoma Relapsed - VIT [vinCRISTine, irinotecan and temozolomide]"/>
</concept>
<concept>
<code value="265541000210105"/>
<display
value="SAR Osteosarcoma Advanced - DOXOrubicin [3-day split dosing] and cISplatin"/>
</concept>
<concept>
<code value="265531000210102"/>
<display
value="LYM NHL B-cell - R-MiniCHOP [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]"/>
</concept>
<concept>
<code value="265521000210104"/>
<display
value="Neuroendocrine carcinoma Advanced - cARBOplatin and oral etoposide"/>
</concept>
<concept>
<code value="265411000210105"/>
<display
value="GU Renal cell Metastatic - aXITinib and avelumab [flat dose]"/>
</concept>
<concept>
<code value="265401000210108"/>
<display value="GU - nivolumab maintenance Q2W [flat dosing]"/>
</concept>
<concept>
<code value="265391000210105"/>
<display
value="GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q2W [flat dosing]"/>
</concept>
<concept>
<code value="265381000210108"/>
<display value="GU - nivolumab maintenance Q4W [flat dosing]"/>
</concept>
<concept>
<code value="265371000210106"/>
<display value="GU - nivolumab and ipilimumab induction"/>
</concept>
<concept>
<code value="265361000210100"/>
<display
value="GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q4W [flat dosing]"/>
</concept>
<concept>
<code value="265351000210103"/>
<display
value="GU URO Metastatic - PACLItaxel Q1W and pembrolizumab Q3W [flat dosing]"/>
</concept>
<concept>
<code value="265341000210101"/>
<display value="GU Renal cell Metastatic - leNVAtinib and everolimus"/>
</concept>
<concept>
<code value="265331000210109"/>
<display
value="GU Bladder Urothelial - gemcitabine [low dose] chemoradiation"/>
</concept>
<concept>
<code value="265321000210107"/>
<display
value="GU Bladder Urothelial Neoadjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense"/>
</concept>
<concept>
<code value="264811000210106"/>
<display value="LEU - daSATinib 140"/>
</concept>
<concept>
<code value="264801000210109"/>
<display value="LEU - daSATinib 100"/>
</concept>
<concept>
<code value="264791000210105"/>
<display value="LEU CML - daSATinib"/>
</concept>
<concept>
<code value="264781000210108"/>
<display value="LEU HCL - cladribine"/>
</concept>
<concept>
<code value="264771000210106"/>
<display value="PCN MM - lenalidomide and dexamethasone"/>
</concept>
<concept>
<code value="264761000210100"/>
<display value="GYN VUL Advanced - ciSplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="264751000210103"/>
<display
value="LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and gemcitabine"/>
</concept>
<concept>
<code value="264741000210101"/>
<display
value="LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and vinORELBine"/>
</concept>
<concept>
<code value="264731000210109"/>
<display
value="SAR Ewing sarcoma Relapsed - irinotecan and temozolomide"/>
</concept>
<concept>
<code value="264721000210107"/>
<display value="Desmoid fibromatosis - metHOTREXATe and vinORELBine"/>
</concept>
<concept>
<code value="264411000210109"/>
<display value="LEU CLL - chlorambucil and oBINUTUZumab"/>
</concept>
<concept>
<code value="264401000210107"/>
<display value="LEU - nilotinib 300"/>
</concept>
<concept>
<code value="264391000210109"/>
<display value="LEU - nilotinib 400"/>
</concept>
<concept>
<code value="264381000210107"/>
<display value="LEU CML - nilotinib"/>
</concept>
<concept>
<code value="264371000210105"/>
<display
value="CNS GBM Recurrent - beVACizumab and irinotecan 340 mg/m2"/>
</concept>
<concept>
<code value="264361000210104"/>
<display
value="LYM Relapsed - ICE [fractionated IFOSFamide, cARBOplatin and etoposide]"/>
</concept>
<concept>
<code value="264351000210102"/>
<display
value="LYM NHL B-cell Relapsed - R-ICE [RITUximab, fractionated IFOSFamide, cARBOplatin and etoposide]"/>
</concept>
<concept>
<code value="264341000210100"/>
<display
value="LYM NHL B-cell MCL - R-BAC [RITUximab, bendamustine and cytarabine]"/>
</concept>
<concept>
<code value="264331000210108"/>
<display
value="LYM NHL B-cell Lymphoplasmacytic - ibrutinib [Waldenström macroglobulinema]"/>
</concept>
<concept>
<code value="264321000210106"/>
<display
value="LYM HL Advanced - ChlVPP [chlorambucil, vinBLASTine, procarbazine and prEDNISone]"/>
</concept>
<concept>
<code value="264011000210104"/>
<display
value="PCN MM Relapsed - pomalidomide, bortezomib and dexamethasone"/>
</concept>
<concept>
<code value="264001000210101"/>
<display value="Myelodysplastic syndrome - azacitidine [7 day]"/>
</concept>
<concept>
<code value="263991000210105"/>
<display value="Myelodysplastic syndrome - azacitidine [5 day]"/>
</concept>
<concept>
<code value="263981000210108"/>
<display
value="LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [60 years and over]"/>
</concept>
<concept>
<code value="263971000210106"/>
<display value="CNS GBM Recurrent - beVACizumab and lomustine"/>
</concept>
<concept>
<code value="263961000210100"/>
<display value="CNS GBM Recurrent - beVACizumab Q2W"/>
</concept>
<concept>
<code value="263951000210103"/>
<display value="CNS GBM Recurrent - beVACizumab Q3W"/>
</concept>
<concept>
<code value="263941000210101"/>
<display value="CNS GLI Recurrent - temozolomide [high grade]"/>
</concept>
<concept>
<code value="263931000210109"/>
<display value="CNS - temozolomide following chemoradiation"/>
</concept>
<concept>
<code value="263921000210107"/>
<display value="CNS - temozolomide chemoradiation"/>
</concept>
<concept>
<code value="60091000210105"/>
<display
value="GYN - cARBOplatin and PACLItaxel [following chemoradiation]"/>
</concept>
<concept>
<code value="60081000210108"/>
<display value="GYN - cISplatin chemoradiation"/>
</concept>
<concept>
<code value="60071000210106"/>
<display
value="GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel"/>
</concept>
<concept>
<code value="60061000210100"/>
<display value="GYN OV Recurrent - topotecan"/>
</concept>
<concept>
<code value="60051000210103"/>
<display
value="GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only]"/>
</concept>
<concept>
<code value="60041000210101"/>
<display value="GYN VUL Advanced - CARBOplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="60031000210109"/>
<display value="GYN OV Recurrent - topotecan and beVACizumab Q4W"/>
</concept>
<concept>
<code value="60021000210107"/>
<display
value="GYN GTD - TP-TE [PACLItaxel, cISplatin - PACLItaxel and etoposide] [relapsed or high risk]"/>
</concept>
<concept>
<code value="60011000210102"/>
<display
value="GYN GTD - EP-EMA [etoposide, ciSplatin, etoposide, metHOTREXATe and daCTINomycin] [high risk]"/>
</concept>
<concept>
<code value="60001000210104"/>
<display
value="GYN OV Low grade serous carcinoma - letrozole maintenance"/>
</concept>
<concept>
<code value="59991000210107"/>
<display value="GYN OV Recurrent - CYCLOPHOSPHamide oral [2/4 dosing]"/>
</concept>
<concept>
<code value="59981000210105"/>
<display value="GYN OV Recurrent - CYCLOPHOSPHamide oral [continuous]"/>
</concept>
<concept>
<code value="59971000210108"/>
<display value="GYN OV Recurrent - etoposide oral"/>
</concept>
<concept>
<code value="59961000210102"/>
<display value="GYN OV Recurrent - gemcitabine"/>
</concept>
<concept>
<code value="59951000210100"/>
<display
value="GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride"/>
</concept>
<concept>
<code value="59941000210103"/>
<display
value="GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride and beVACizumab"/>
</concept>
<concept>
<code value="59931000210106"/>
<display
value="GYN CX Locally advanced - cARBOplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="59921000210109"/>
<display
value="GYN CX Locally advanced - cISplatin [Q1W] chemoradiation"/>
</concept>
<concept>
<code value="59911000210104"/>
<display
value="GYN GTD - EMA-CO [etoposide, metHOTREXATe, daCTINomycin, CYCLOPHOSPHamide and vinCRISTine] [high risk]"/>
</concept>
<concept>
<code value="59901000210101"/>
<display
value="LUNG NSCLC Locally advanced - durvalumab Q2W [weight based dosing]"/>
</concept>
<concept>
<code value="496201000210103"/>
<display value="Malignancy, direct spread to cervix and/or vagina"/>
</concept>
<concept>
<code value="496211000210101"/>
<display value="Cervix specimen from partial hysterectomy"/>
</concept>
<concept>
<code value="496231000210108"/>
<display value="Cervix specimen from total hysterectomy"/>
</concept>
<concept>
<code value="496241000210100"/>
<display value="Polyp specimen"/>
</concept>
<concept>
<code value="496191000210100"/>
<display value="Endocervical adenocarcinoma, superficially invasive"/>
</concept>
<concept>
<code value="497441000210104"/>
<display value="SACT regimen type"/>
</concept>
<concept>
<code value="497451000210101"/>
<display value="Prescribed dose unit"/>
</concept>
<concept>
<code value="497461000210103"/>
<display value="Administered dose unit"/>
</concept>
<concept>
<code value="495991000210106"/>
<display value="Tumour width"/>
</concept>
<concept>
<code value="496001000210105"/>
<display value="Tumour depth"/>
</concept>
<concept>
<code value="495981000210109"/>
<display value="Tumour length"/>
</concept>
<concept>
<code value="7283002"/>
<display value="Base of tongue"/>
</concept>
<concept>
<code value="1340143004"/>
<display value="Intrahepatic bile duct"/>
</concept>
<concept>
<code value="505941000210108"/>
<display value="Extra-adrenal paraganglioma primary"/>
</concept>
<concept>
<code value="507401000210108"/>
<display value="Histopathology request"/>
</concept>
<concept>
<code value="507411000210105"/>
<display value="Histopathology report"/>
</concept>
</CodeSystem>